# Study of Optimized Management of Nivolumab Based on Response in Patients With Advanced RCC (OMNIVORE Study)

> **NCT03203473** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Toni Choueiri, MD** · enrollment: 85 (actual)

## Conditions studied

- Renal Cancer

## Interventions

- **DRUG:** Ipilimumab
- **DRUG:** Nivolumab

## Key facts

- **NCT ID:** NCT03203473
- **Lead sponsor:** Toni Choueiri, MD
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2017-10-26
- **Primary completion:** 2021-11-30
- **Final completion:** 2026-06-28
- **Target enrollment:** 85 (ACTUAL)
- **Last updated:** 2026-02-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03203473

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03203473, "Study of Optimized Management of Nivolumab Based on Response in Patients With Advanced RCC (OMNIVORE Study)". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03203473. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*